

**Table 1. ATC-codes used to define DMARDs and topical emollients**

Drug group	ATC-code	Generic name
<b>Biologic DMARDs</b>	L04AA24	Abatacept
	L04AB01	Etanercept
	L04AA21	Efalizumab*
	L04AB02	Infliximab**
	L04AB04	Adalimumab
	L04AB05	Certolizumabpegol
	L04AB06	Golimumab
	L04AC03	Anakinra
	L04AC05	Ustekinumab
	L04AC07	Tocilizumab
<b>Non-biologic DMARDs</b>	L01XC02	Rituximab
	A07EC01	Sulfasalazine
	D05BB02	Acitretin
	L04AA15	Leflunomid
	L04AD01	Ciklosporin
	L04AX01	Azathioprine
	L01BA01	Methotrexate
	L04AX03	
	M01CB01	Natriumaurotiomalat
	M01CB03	Auranofin
<b>Topical emollients</b>	P01BA01	Chloroquine
	P01 BA02	Hydroxychloroquine
	D05AA	Tjäror
	D05AC01	Ditranol
	D05AX01	Fumarsyra
	D05AX02	Kalcipotriol
	D05AX52	Kalcipotriol + betametason
	D07AC01	Betametason
	D07CC01	Betametason + antibiotika
	D07AC17	Flutikason

  

D07AC13	Mometason
D07AB02	Hydrokortisonbutyrat
D07AD01	Klobetasol
D07AB01	Klobetasol

DMARD=Disease Modifying AntiRheumatic Drugs

\*Not on the market after 20090609

\*\*Infliximab is given as infusion in hospitals and therefore not included in the cost component "Drugs" in our presentation of resource use and associated costs.

Online supplement to Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity? *The Journal of Rheumatology*, doi:10.3899/jrheum.150406

**Table 2A. Mean annual use and associated costs per patient for healthcare and work loss by cost component during 2008-2011.**

	PSO/PsA patients (N=15 283)		Referents (N=45 849)		Mean cost	P-value				
	Resource	Mean cost	Resource	Mean cost	difference					
		use*		(SD)**						
<b>HEALTHCARE</b>										
<b>Primary care consultations</b>										
Physician	1.9 (1.9)	273 (270)	1.6 (1.7)	220 (282)	53	<0.0001				
Nurse	1.8 (4.1)	111 (253)	1.4 (3.0)	84 (200)	28	<0.0001				
PT/OT	1.5 (5.1)	87 (283)	1.2 (4.2)	66 (231)	21	<0.0001				
Other	0.14 (0.7)	10 (54)	0.12 (0.7)	9 (52)	2	<0.0001				
<i>Total primary care costs</i>		482 (556)		379 (489)	103	<0.0001				
<b>Secondary outpatient care</b>										
<b>consultations</b>										
Dermatologist, rheumatologist or internist	1.0 (4.0)	305 (1855)	0.39 (2.3)	116 (1028)	189	<0.0001				
Other specialist	2.1 (4.3)	658 (1722)	1.6 (2.7)	512 (1095)	146	<0.0001				
Nurse	2.0 (7.1)	257 (1112)	0.69 (3.9)	132 (874)	125	<0.0001				
PT/OT	0.3 (2.7)	36 (307)	0.16 (1.5)	18 (164)	18	<0.0001				
Other	0.5 (2.3)	90 (512)	0.40 (2.1)	66 (425)	24	<0.0001				
<i>Total secondary outpatient care costs</i>		1345 (3235)		844 (2129)	502	<0.0001				
<b>Inpatient care, n days and costs</b>										
	2.5 (9.8)	1790 (5960)	1.8 (8.0)	1313 (4941)	476	<0.0001				
<b>Drug use, % of patients</b>										
Biologic DMARDs	4.6%	427 (2271)	0.3%	21 (493)	406	<0.0001				
Non-biologic DMARDs	13.5%	18 (119)	1.5%	3 (79)	15	<0.0001				

Online supplement to Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity? *The Journal of Rheumatology*, doi:10.3899/jrheum.150406

Topicals	61.1%	61 (189)	15.5%	2 (11)	59	<0.0001
Other drugs	96.0%	626 (1610)	89.6%	463 (1622)	163	<0.0001
<i>Total drug costs</i>	96.8%	1131 (2827)	89.9%	489 (1713)	642	<0.0001
<b>TOTAL HEALTHCARE COSTS</b>		<b>4749 (8763)</b>		<b>3024 (6830)</b>	<b>1724</b>	<b>&lt;0.0001</b>
<b>WORK LOSS</b>						
Sick leave, n days	7.1 (27.8)	997 (3974)	5.1 (23.3)	718 (3345)	279	<0.0001
Disability pension, n days	33.3 (94.5)	4719 (13558)	21.0 (77.0)	2995 (11122)	1724	<0.0001
<i>TOTAL PRODUCTIVITY LOSSES, N DAYS AND COSTS</i>	40.7 (99.4)	5717 (14163)	26.3 (81.6)	3713 (13095)	2004	<0.0001
<b>TOTAL SOCIETAL COSTS</b>		<b>10,465 (18054)</b>		<b>6737 (14651)</b>	<b>3728</b>	<b>&lt;0.0001</b>

\* Mean (SD) if not otherwise stated. \*\* Costs are expressed in Euros. PT=Physiotherapist, OT=Occupational therapist

**Table S2B. Mean annual use and associated costs per patient for healthcare and work loss by cost component during 2008-2011.**

	PSO alone patients (N=12,562)		PsA patients (N=2721)		Mean cost	P-value				
	Resource	Mean cost (SD)**	Resource	Mean cost (SD)**	difference					
					use*	use*				
<b>HEALTHCARE</b>										
<b>Primary care consultations</b>										
Physician	1.9 (2.0)	271 (272)	2.1 (1.9)	286 (262)	15	0.0103				
Nurse	1.8 (4.0)	109 (249)	2.1 (4.6)	124 (274)	15	0.0048				
PT/OT	1.4 (4.6)	77 (259)	2.3 (6.7)	130 (374)	53	<0.0001				
Other	0.14 (0.7)	10 (53)	0.17 (0.8)	12 (58)	2	0.0829				
<i>Total primary care costs</i>		<b>467 (540)</b>		<b>552 (622)</b>	<b>85</b>	<b>&lt;0.0001</b>				
<b>Secondary outpatient care</b>										
<b>consultations</b>										

Online supplement to Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity? *The Journal of Rheumatology*, doi:10.3899/jrheum.150406

Dermatologist, rheumatologist or internist	0.81 (4.1)	217 (1644)	2.0 (3.6)	714 (2581)	497	<0.0001
Other specialist	2.0 (4.4)	636 (1809)	2.4 (3.4)	760 (1243)	125	0.0006
Nurse	1.9 (6.9)	240 (1065)	2.3 (8.0)	333 (1307)	93	0.0001
PT/OT	0.20 (1.7)	22 (194)	0.97 (5.4)	100 (590)	78	<0.0001
Other	0.52 (2.4)	88 (512)	0.60 (1.9)	98 (363)	10	0.3458
<i>Total secondary outpatient care costs</i>		1203 (3134)		2005 (3593)	802	<0.0001
<b>Inpatient care, n days and costs</b>	<b>2.6 (10.3)</b>	<b>1778 (6121)</b>	<b>2.3 (7.0)</b>	<b>1841 (5149)</b>	<b>63</b>	<b>0.6165</b>
<b>Drug use, % of patients</b>						
Biologic DMARDs	1.7%	147 (1312)	17.9%	1718 (4358)	1568	<0.0001
Non-biologic DMARDs	7.0%	9 (85)	43.8%	63 (210)	54	<0.0001
Topicals	61.4%	60 (172)	59.5%	65 (254)	5	0.2154
Other drugs	95.4%	600 (1622)	98.8%	742 (1554)	141	<0.0001
<i>Total drug costs</i>	<i>96.4%</i>	<i>816 (2118)</i>	<i>99.0%</i>	<i>2585 (4651)</i>	<i>1768</i>	<i>&lt;0.0001</i>
<b>TOTAL HEALTHCARE COSTS</b>		<b>4264 (8596)</b>		<b>6984 (9173)</b>	<b>2720</b>	<b>&lt;0.0001</b>
<b>WORK LOSS</b>						
Sick leave, n days	6.2 (26.2)	878 (3788)	11.1 (33.7)	1549 (4700)	670	<0.0001
Disability pension, n days	26.4 (85.7)	3789 (12469)	65.2 (122.5)	9018 (17097)	5229	<0.0001
<i>TOTAL PRODUCTIVITY LOSSES, N DAYS AND COSTS</i>	<i>32.9 (90.6)</i>	<i>4666 (13072)</i>	<i>76.7 (126.4)</i>	<i>10,566 (17587)</i>	<i>5900</i>	<i>&lt;0.0001</i>
<b>TOTAL SOCIETAL COSTS</b>		<b>8931 (16959)</b>		<b>17,550 (21025)</b>	<b>8620</b>	<b>&lt;0.0001</b>

\* Mean (SD) if not otherwise stated. \*\* Costs are expressed in Euros. PT=Physiotherapist, OT=Occupational therapist